Imdelltra (tarlatamab-dlle) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345678910»
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations. (Pubmed Central) -  May 7, 2026   
    TCEs have achieved major success in hematologic malignancies and now show promise in selected solid tumors, with the approvals of tebentafusp and tarlatamab in uveal melanoma and small cell lung cancer, respectively, establishing proof of concept that durable benefit is possible...ADC-checkpoint inhibitor combinations are similarly reshaping solid tumor therapy, most notably in urothelial carcinoma, where enfortumab vedotin plus pembrolizumab has demonstrated substantial survival gains...Emerging drug engineering approaches and biomarker-driven patient selection aim to improve efficacy while limiting toxicity. Together, these advances support a new era of precision immuno-oncology, but broader success will require improved biomarkers, rational combinations, and an understanding of resistance mechanisms.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance. (Pubmed Central) -  Apr 29, 2026   
    Platinum-etoposide has long been the standard first-line therapy, and the recent incorporation of immune checkpoint inhibitors (ICIs) such as atezolizumab (IMpower133) and durvalumab (CASPIAN, ADRIATIC) has modestly improved survival, including a new role for durvalumab as a consolidation therapy in limited-stage SCLC...Emerging approaches include DLL3-directed bispecific T-cell engagers (BiTEs), such as tarlatamab and obrixtamig, which have shown promising efficacy in relapsed disease, and next-generation antibody-drug conjugates (ADCs) targeting DLL3, B7-H3, TROP2, and SEZ6...Future therapeutic efforts will require biomarker-driven strategies that incorporate molecular subtyping (ASCL1, NEUROD1, POU2F3, and YAP1) and immune profiling to facilitate precise treatment selection. Combining ICIs, BiTEs, ADCs, and cellular or radioligand therapies in rational, evidence-based regimens represents a promising avenue to improve outcomes in this historically intractable disease.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Tarlatamab in small cell lung cancer with brain metastases: A real-world experience. (Hall A - Posters and Exhibits; Poster Bd #: 582) -  Apr 21, 2026 - Abstract #ASCO2026ASCO_2524;    
    Clinical Trial Registration Number: NCT05740566 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Noninvasive imaging biomarkers for survival risk stratification with tarlatamab in ES-SCLC. (Hall A - Posters and Exhibits; Poster Bd #: 494) -  Apr 21, 2026 - Abstract #ASCO2026ASCO_2501;    
    The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, Lung Cancer research Program Career Development Award, Lung Cancer Research Program The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Impact of DLL3 expression and tumor subtype on response to tarlatamab. (Hall A - Posters and Exhibits; Poster Bd #: 561) -  Apr 21, 2026 - Abstract #ASCO2026ASCO_2487;    
    Funded by National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, National Cancer Institute, Lung Cancer research Program Career Development Award, Lung Cancer Research Program The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    REAL-WORLD EXPERIENCE WITH TARLATAMAB IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (Exhibit Hall I2) -  Mar 28, 2026 - Abstract #HOPA2026HOPA_425;    
    Conclusion In this real-world analysis, grade 2 CRS and ICANS were the most severe toxicities observed, and clinical benefit was achieved despite these events. Oncology clinical pharmacists play a vital role in optimizing safety, clinical outcomes, and healthcare resource utilization in patients receiving BiTE therapy.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Real world experience with lurbinectedin for the management of relapsed/refractory extensive stage small cell lung cancer (Exhibit Hall I2) -  Mar 28, 2026 - Abstract #HOPA2026HOPA_420;    
    These include lurbinectedin and tarlatamab.1, 3 Lurbinectedin and tarlatamab carry preferred therapy recommendations from the National Comprehensive Cancer Network; tarlatamab is category 1 while lurbinectedin is 2A.1 Despite stronger evidence for efficacy in the relapsed setting, tarlatamab may not be appropriate for, or accessible for, all patients with ES-SCLC. Research in progress.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    LB02: Hybrid Observation Model for Bispecific T-Cell Engagers (HOME) (Exhibit Hall I2) -  Mar 28, 2026 - Abstract #HOPA2026HOPA_324;    
    A hybrid observation model can be safely utilized for oncology patients receiving tarlatamab to monitor for and manage CRS and ICANS. This allows for improved patient satisfaction and the ability to appropriately charge for these ambulatory services.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    B-NDG MHC I/II DKO mice plus: A refined humanized model for evaluating T cell engager efficacy and toxicity (Section 8) -  Mar 17, 2026 - Abstract #AACR2026AACR_9447;    
    B-NDG MHC I/II DKO mice plus effectively alleviate human PBMC-induced GvHD while retaining normal antibody pharmacokinetics and enabling reliable assessment of TCE anti-tumor efficacy and cytokine-mediated toxicity. This model provides a refined and translationally relevant platform for preclinical evaluation of TCE therapeutics.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Tumor cell surface targeting of high-grade neuroendocrine carcinomas (Section 16) -  Mar 17, 2026 - Abstract #AACR2026AACR_7632;    
    DLL3 levels have been evaluated by CLIA-validated immunohistochemistry in >340 patients at MDACC, including those diagnosed with rare extrapulmonary hgNECs (i.e., Merkel cell carcinoma, small cell of the breast, thyroid, etc.) for off-label use of tarlatamab (DLL3-targeting TCE)...Surface-targeting therapies represent a new paradigm for hgNEC therapeutics and while DLL3- and SEZ6-targeting therapies are showing promise across all hgNECs, their impact will be limited outside SCLC without patient selection. Utilizing biomarkers, including those for target expression, inflammatory potential, and payload sensitivity, will be critical to optimize drug selection for patients with these malignancies.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Analysis of RNA expression of 47 cell surface proteins in real-world small cell lung cancer patients (Section 46) -  Mar 17, 2026 - Abstract #AACR2026AACR_6881;    
    The biparatopic DLL3/CD3 TCE exhibits robust preclinical efficacy and a favorable safety profile, supporting its further development as a targeted immunotherapy for DLL3-positive SCLC and NECs. Almost all patients relapse after initial induction chemotherapy and immunotherapy, and clinical benefit from subsequent therapies including tarlatamab-dlle (a DLL3 bispecific T cell engager) are limited...With respect to treatment status, we detected significantly (p<0.05) higher expression of CTLA4, PDCD1, TIGIT, TACSTD2, and ITGB6 in treatment-na